Key Points
- Longer-term data on use of stem cells to treat incontinence and data on stem cells as a treatment in men who have undergone
prostate surgery
- Ability of the obturator approach to sling surgery to prevent certain complications
- Maturing data on use of botulinum toxin therapy to treat overactive bladder
 Shlomo Raz, MD
|
Developments in stem cell therapy, new minimally invasive sling procedures, and research on botulinum toxin (Botox) therapy
for overactive bladder soon will give urologists far more effective treatment for incontinence than they can offer their patients
today, said Shlomo Raz, MD, co-director of the division of female urology, reconstructive surgery, and urodynamics at UCLA.
Urologists began to hear about stem cell use in incontinence therapy at the 2004 AUA meeting. This year's meeting brings more
research on the use of muscle-derived stem cells from those same scientists, who will present longer-term data and discuss
their use of stem cells in other groups of patients, such as for treating incontinence in men after prostate surgery.
Other new approaches are being tried. Researchers from UCLA are using autologous fat as a new source of stem cells for intraurethral
injection to treat incontinence. Clearly, stem cell therapies hold promise in the not-too-distant future.
"Adipose-derived stem cells are still in the experimental stage. We don't have long-term results on the skeletal-derived muscle
cells, but the initial results are very promising. If these results are confirmed, stem cell techniques for incontinence might
be incorporated into routine clinical use in 3 to 5 years," Dr. Raz told Urology Times. New approach to slings
 What to Watch for
|
Something urologists can take away from this year's meeting and incorporate into their practices now is an obturator approach
to sling surgery that has been investigated recently. Major complications, such as bleeding or perforations, have been reported
with the retropubic approach, where the needle is transferred through the retropubic space from the vagina up to the suprapubic
area or from the suprapubic down. The obturator approach prevents these complications, Dr. Raz explained.
"It's easier for urologists to do, and it has fewer complications. It may not be as effective, but we don't have long-term
data yet," he said.
Although using biomaterials for slings held promise, their use is fading, and synthetic materials are now overwhelmingly used,
Dr. Raz said.
"The durability of the biomaterials is in doubt because the body reabsorbs them. The body does not as easily transform a biomaterial
into a strong layer of tissue," he explained. "But the synthetic materials create a frame for the patient's own tissue to
grow and create a durable and strong support."
At the upcoming AUA meeting, urologists also will hear about new techniques and kits from synthetic materials being used in
prolapse surgery.
Data are maturing on the use of botulinum toxin injections for overactive bladder. These techniques could be a boon to both
urologists and their patients, Dr. Raz said. Injections can be done in the office under local anesthesia with minimal morbidity
and relatively good results.
"If, indeed, it is shown that it is effective, botulinum toxin can be a viable alternative to the use of anticholinergic agents
or neuromodulation. At present, the long-term use of botulinum toxin is unknown.
"It's something to try when a patient has had other overactive bladder treatments fail," said Dr. Raz.